JP2015527978A5 - - Google Patents

Download PDF

Info

Publication number
JP2015527978A5
JP2015527978A5 JP2015518629A JP2015518629A JP2015527978A5 JP 2015527978 A5 JP2015527978 A5 JP 2015527978A5 JP 2015518629 A JP2015518629 A JP 2015518629A JP 2015518629 A JP2015518629 A JP 2015518629A JP 2015527978 A5 JP2015527978 A5 JP 2015527978A5
Authority
JP
Japan
Prior art keywords
seq
sequence number
cancer
antibody
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527978A (ja
JP6438391B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/047192 external-priority patent/WO2013192596A2/en
Publication of JP2015527978A publication Critical patent/JP2015527978A/ja
Publication of JP2015527978A5 publication Critical patent/JP2015527978A5/ja
Application granted granted Critical
Publication of JP6438391B2 publication Critical patent/JP6438391B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518629A 2012-06-22 2013-06-21 Ccr2に結合する抗原結合タンパク質 Expired - Fee Related JP6438391B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663496P 2012-06-22 2012-06-22
US61/663,496 2012-06-22
PCT/US2013/047192 WO2013192596A2 (en) 2012-06-22 2013-06-21 Antigen binding proteins that bind ccr2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018141655A Division JP2018199681A (ja) 2012-06-22 2018-07-27 Ccr2に結合する抗原結合タンパク質

Publications (3)

Publication Number Publication Date
JP2015527978A JP2015527978A (ja) 2015-09-24
JP2015527978A5 true JP2015527978A5 (enExample) 2016-08-12
JP6438391B2 JP6438391B2 (ja) 2018-12-12

Family

ID=49769736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015518629A Expired - Fee Related JP6438391B2 (ja) 2012-06-22 2013-06-21 Ccr2に結合する抗原結合タンパク質
JP2018141655A Withdrawn JP2018199681A (ja) 2012-06-22 2018-07-27 Ccr2に結合する抗原結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018141655A Withdrawn JP2018199681A (ja) 2012-06-22 2018-07-27 Ccr2に結合する抗原結合タンパク質

Country Status (7)

Country Link
US (3) US9315579B2 (enExample)
EP (1) EP2864358B1 (enExample)
JP (2) JP6438391B2 (enExample)
CN (1) CN105051065A (enExample)
CA (1) CA2877814A1 (enExample)
HK (1) HK1208236A1 (enExample)
WO (1) WO2013192596A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835419B2 (en) 2011-12-01 2014-09-16 Chemocentryx, Inc. Substituted anilines as CCR(4) antagonists
HK1208181A1 (en) 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
CN105051065A (zh) 2012-06-22 2015-11-11 索伦托治疗有限公司 与ccr2结合的抗原结合蛋白
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
WO2017165125A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
US20170348442A1 (en) 2016-06-02 2017-12-07 Washington University Compositions and methods for detecting ccr2 receptors
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3612563A1 (en) * 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
EP3687525B1 (en) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス,インコーポレーテッド 多重特異性分子及びその使用
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112105353B (zh) * 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス,インコーポレーテッド Csf1r/ccr2多特異性抗体
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2023072916A1 (en) 2021-10-27 2023-05-04 Granite Bio Ag Antibodies targeting ccr2
WO2024220548A2 (en) * 2023-04-17 2024-10-24 University Of Southern California Molecular-mri using ccr2-targeted micelles for detection of lymph node metastases
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体
WO2025231346A1 (en) * 2024-05-03 2025-11-06 The Wistar Institute Of Anatomy And Biology Anti-interferon-alpha and anti-interferon-beta antibodies, and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20070021466A1 (en) 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
WO2004110376A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Ccr-2 antagonists for treatment of neuropathic pain
WO2005060368A2 (en) 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
BRPI0718225A2 (pt) * 2006-10-05 2013-11-12 Centocor Ortho Biotech Inc Antagonistas de ccr2 para tratamento de fibrose
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
CN105051065A (zh) * 2012-06-22 2015-11-11 索伦托治疗有限公司 与ccr2结合的抗原结合蛋白
JP2020101482A (ja) 2018-12-25 2020-07-02 セイコーエプソン株式会社 外観検査補助装置および外観検査補助方法

Similar Documents

Publication Publication Date Title
CN105837688B (zh) 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞
RU2016136639A (ru) Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины
HRP20200241T1 (hr) Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti
JP2012501669A5 (enExample)
JP2020500542A5 (enExample)
JP2016515524A5 (enExample)
JP2012500020A5 (enExample)
RU2009128215A (ru) Человеческие антитела, которые связываются с человеческим il-12, и способы получения
TN2015000348A1 (en) Antibodies that bind il-23
JP2014500009A5 (enExample)
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
EA201370105A1 (ru) Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a)
JP2017523984A5 (enExample)
JP2017512838A5 (enExample)
RU2019126888A (ru) Антитело к человеческому аннексину а1
JP2019524730A5 (enExample)
RU2015144033A (ru) Антитела против cd25 и их применения
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
Chan et al. Affinity maturation: highlights in the application of in vitro strategies for the directed evolution of antibodies
JP2016520595A5 (enExample)
CN106188298A (zh) 一种Vsig4纳米抗体及其抗原表位鉴定方法和应用
JP2019516785A5 (enExample)
Yu et al. Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2
CN119060194A (zh) 一种靶向b细胞的双特异性纳米抗体及其应用
JP2020505465A5 (enExample)